Atara Biotherapeutics (ATRA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

Atara Biotherapeutics is halving its headcount as it navigates the fallout from the FDA’s move to halt trials of the ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Atara Biotherapeutics (ATRA – Research Report) yesterday and set a price ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Corporate Activity and Growth category. Atara Biotherapeutics Inc faces ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) yesterday. The company’s shares closed ...

Atara Biotherapeutics said it would lay off half of its workforce in a restructuring that came as the company narrowed its loss and logged higher revenue in the fourth quarter. The immunotherapy ...

Atara Biotherapeutics has a 12-month low of $5.40 and a 12-month high of $20.81. Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last issued its quarterly earnings results on Friday, March ...

Atara is working closely with its partners ... preserve resources Strategic review by financial advisor ongoing Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...